Enlivex Therapeutics Ltd.
ENLVHealthcare|Biotechnology|IL
$1.27
+0.00 (+0.00%)
Tangible Book / Share
$2661.47
Graham Number
$18359.01
Cash / Share
$5.34
About
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Stock Price
-99.5%(1Y)
1M
-71.3%
3M
-96.2%
6M
-99.3%
YTD
-99.2%
1Y
-99.5%
3Y
-99.7%
5Y
-99.9%
Pipeline Summary
10 total trials6
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
Active: 1Completed: 3Terminated: 4Recruiting: 1Unknown: 1
Active Trials (2)
Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety
NCT06208241Knee Osteoarthritis
Early P1Active
Enrollment: 18 participants
Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
NCT07580716Primary Knee Osteoarthritis
Phase 2Recruiting
Enrollment: 182 participants
Key Facts
Market Cap$21.4M
Employees34
CEOOren Hershkovitz
IPO DateJul 31, 2014
Beta1.41
52-Week Range$1.22 – $434.4
Avg Volume55,348
ExchangeNASDAQ
Websiteenlivex.com
Ownership
Float99.5%
Shares Outstanding16.8M
Recent Insider Trades
Hershkovitz OrenOTHER
Mar 18, 20260 shares
Hershkovitz OrenOTHER
Nov 16, 2023150,000 shares @ $8.19
Hershkovitz OrenOTHER
Nov 24, 202560,000 shares @ $5.34
Shlosberger ShacharOTHER
Mar 18, 20260 shares
Shlosberger ShacharOTHER
Mar 7, 20211,452 shares @ $2.69
Peers
Recent News
Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
Nov 2, 2026 · globenewswire.com
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Oct 28, 2026 · globenewswire.com
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Oct 27, 2026 · globenewswire.com
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Oct 22, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:08 AM